logo

FDA Calendar

PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.

The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.

Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
Company Name
Drug
Event
Outcome
Details
Ligand Pharmaceuticals Inc
(LGND)
Sparsentan(NDA)
02/17/2023
FDA decision on Sparsentan for the treatment of IgA nephropathy
FDA granted accelerated approval for Sparsentan, under brand name FILSPARI, to reduce proteinuria in adults with primary IgAN, on Feb.18, 2023-
Radius Health, Inc.
(RDUS)
Elacestrant (NDA)
02/17/2023
FDA decision on Elacestrant for treatment of ER+/HER2- advanced or metastatic breast cancer
FDA approved Elacestrant, under brand name Orserdu, for treatment of ER+/HER2- advanced or metastatic breast cancer on Jan.27, 2023-
Apellis Pharmaceuticals, Inc.
(APLS)
Syfovre (pegcetacoplan injection) (NDA)
02/26/2023
FDA decision on Pegcetacoplan for the treatment of Geographic Atrophy secondary to age-related macular degeneration
FDA approves Syfovre (pegcetacoplan injection) for Geographic Atrophy secondary to age-related macular degeneration on Feb 17, 2023-
Pfizer Inc.
(PFE)
ABRYSVO (BLA)
02/28/2023
FDA panel to review ABRYSVO RSVpreF for active immunization for the prevention of acute respiratory disease and lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older
FDA panel voted 7 to 4 on safety and 7 to 4 on effectiveness, recommending approval of ABRYSVO RSVpreF vaccine to help combat RSV in older adults on Feb.28, 2023. -
Royalty Pharma plc
(RPRX)
Omecamtiv mecarbil (NDA)
02/28/2023
FDA decision on Omecamtiv mecarbil for heart failure with reduced ejection fraction (HFrEF)
FDA declined to approve Omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction on Feb.28, 2023-
Sanofi
( SNYNF, SNY)
Efanesoctocog alfa (BIVV001) (BLA)
02/28/2023
FDA decision on efanesoctocog alfa for the treatement of hemophilia A
FDA approved Efanesoctocog alfa under brand name ALTUVIIIO on Feb.24, 2023-
Reata Pharmaceuticals, Inc.
(RETA)
Omaveloxolone (NDA)
02/28/2023
FDA decision on Omaveloxolone for the treatment of patients with Friedreich’s Ataxia
FDA approved Omaveloxolone, under brand name SKYCLARYS, for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older on Feb.28, 2023-
Cytokinetics Inc.
(CYTK)
Omecamtiv mecarbil (NDA)
02/28/2023
FDA decision on Omecamtiv mecarbil for heart failure with reduced ejection fraction (HFrEF)
FDA denies FDA approval for Omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction on Feb.28, 2023-
Regeneron Pharmaceuticals
(REGN)
EYLEA (sBLA)
02/28/2023
FDA decision to approve EYLEA for every 16-week dosing regimen in patients with Diabetic Retinopathy
Pending-
GSK plc
(GSK.L, GSK)
AREXVY (BLA)
03/01/2023
FDA panel to review AREXVY for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older
FDA panel voted unanimously recommending approval of Arexvy for prevention of RSV-linked lower respiratory tract disease in adults 60 years of age and older on Mar.1, 2023-

ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.

Buy this Content

How to Read an FDA Calendar?

Before you can use an FDA Calendar, it's important to understand how to read and interpret it. An FDA Calendar typically displays information about the expected timeline for a particular drug approval or PDUFA date. The calendar will also provide key information such as what type of approval is being sought (e.g. full approval, tentative approval, accelerated approval), and any publicly available information about the expected decision date.



Biogen Inc. (BIIB) reported Phase 1b clinical data showing that the investigational antisense oligonucleotide therapy, BIIB080, reduced soluble tau protein in cerebrospinal fluid in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease. BIIB080 also reduced aggregated...
Viking Therapeutics Inc. (VKTX), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced Tuesday positive results from Phase 1 clinical trial of Dual GLP-1/GIP Receptor Agonist VK2735. Based on these results from Phase 1 single ascending dose or SAD and multiple...
Monopar Therapeutics Inc. (MNPR) announced completion of a pre-specified interim analysis for its Validive Phase 2b/3 VOICE trial for the prevention of severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. The trial did not meet the pre-defined threshold for efficacy...
Read More
The World Health Organization's Strategic Advisory Group of Experts on Immunization (SAGE) revised the roadmap for prioritizing the use of Covid-19 vaccines to reflect the impact of Omicron and high population-level immunity acquired by infection and vaccination. WHO experts recommended that healthy kids and teenagers are considered as "low risk" category and may not necessarily need vaccine aga
President Joe Biden has signed the Covid Origins Act of 2023 into law. The legislation requires the Biden administration to declassify intelligence related to any potential links between the Wuhan Institute of Virology and the origins of the Covid pandemic within 90 days of enactment.
A significant decrease in the number of Covid cases and deaths has been reported in the United States in the past two weeks. Coronavirus infections fell by 34 percent and deaths due to the virus disease reduced by 38 percent nationally, according to the latest data shared by the New York Times. Other Covid metrics also indicate the slowing down of the pandemic. Hospitalizations have been fallin
Read More